RecruitingOverweightObesityType 2 Diabetes
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.
Sponsor: Novo Nordisk A/S
You may qualify if…
- ✓ Male or female (sex assigned at birth, inclusive of all gender identities).
- ✓ Age 18 years or older at the time of signing the informed consent.
- ✓ Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
- ✓ Participants on a stable treatment dose of tirzepatide for at least 4 weeks.
- ✓ Only for participants with T2D:
- ✓ Diagnosed with type 2 diabetes before screening.
- ✓ Treatment with 0-2 marketed oral glucose-lowering medications (metformin or sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a single agent or in combination) according to local label. Treatment with oral glucose-lowering medications must be stable (same drug(s), stable daily doses) for at least 90 days before screening.
You may not qualify if…
- ✕ Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- ✕ History of reduction in dose of tirzepatide, due to intolerability, without successful reescalation.
- ✕ Presence of any clinically relevant condition that causes symptoms which are similar to the gastrointestinal adverse events (GI AEs) linked to glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment, and which could confound evaluation of GLP-1 RA-related GI AEs and tolerability endpoints.
- ✕ Ongoing use of medications causing clinically relevant gastrointestinal symptoms that could confound evaluation of GLP-1 RA-related GI AEs and tolerability endpoints, as judged by the investigator.
- ✕ Use of prescription medicinal products or non-prescription drugs within 14 days before screening. Exceptions are:
- ✕ use of tirzepatide as described in inclusion criterion 5
- ✕ glucose-lowering medication mentioned in inclusion criterion 7 (only for participants with T2D)
- ✕ stable use (initiated minimum 30 days before screening) of statins, blood pressure lowering medicine, beta blockers
Where it's recruiting
California
Glendale
Maryland
Baltimore
Source: ClinicalTrials.gov · NCT07868354 · last updated 2026-10-16